Table 4. Ki-67 expression at baseline and after treatment.
| Description | P-value | ||
|---|---|---|---|
|
Overall | |||
| Pre-treatment | Median 14.5% (range 2–90%) | P<0.000001 | |
| Post-treatment |
Median 2% (range 0–95%) |
|
|
|
Cohort A | |||
| Pre-treatment | Median 13% (5–35%) | P<0.00001 | |
| Post-treatment |
Median 2% (0–50%) |
|
|
|
Cohort B | |||
| Pre-treatment | Median 13.5% (2–90%) | P<0.00001 | P=not significant |
| Post-treatment |
Median 2% (0–95%) |
|
|
|
Cohort C | |||
| Pre-treatment | Median 15% (2–32%) | P<0.0001 | |
| Post-treatment | Median 3% (0–40%) | ||
Letrozole induced an overall significant reduction of Ki-67 expression after treatment. The significant reduction was detected in each single cohort. No significant differences in Ki-67 suppression after treatment were observed among each cohort.